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Abstract
Introduction. The main component of extralysosomal proteolysis is the ubiquitin-proteasome system (UPS), 
which is supplemented by tripeptidyl peptidase II (TPPII). That system is a target for anticancer strategies 
by using proteasome inhibitors. Data from several studies on leukemic cells share evidence for the beneficial 
and potential role of TPPII in cell survivability. Therefore, the aim of this work was to analyze the effect of 
AAF-cmk, a membrane permeable semi-specific TPPII inhibitor, on human monocytic leukemic cells U937 for 
translational research. 
Material and methods. We studied the viability of U937 cells incubated with AAF-cmk using tetrazolium salt 
reduction assay (MTT) and apoptosis induction by assessing caspase activation by Western blotting and An-
nexin V binding assays. Transmission electron microscopy (TEM), a gold standard for apoptosis and autophagy 
detection, was used to assess the ultrastructure of U937 cells.
Results. Incubation of cells with AAF-cmk reduced their viability and induced apoptosis by intrinsic pathway. 
In groups treated with AAF-cmk, activation of caspases 9 and 3 was observed and caspase inhibition by zVDA 
restored cell viability. TEM revealed the presence of ultrastructural features of apoptosis and authophagy. 
Moreover, we identified two types of protein aggregates. The first one was found in close proximity to the en-
doplasmic reticulum (ER) and corresponds to Aggresome-Like Structure (ALIS); however, the second novel 
type of aggregate was not related to ER elements, but rather to free cytosolic ribosomes. This type did not corre-
spond to the aggresome neither in localization nor the structure, thus we referred these aggregates as ALiSNER 
(Aggresome-Like Structure Not Associated With the ER).
Conclusions. Our results provide novel and important findings about the role of TPPII in protein homeostasis 
and cell survival. Since semispecific TPPII inhibitor AAF-cmk displays cytotoxic activity against leukemic U937 
cells in vitro it can be considered as a potential anticancer agent. (Folia Histochemica et Cytobiologica 2018, Vol. 
56, No. 4, 185–194)
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Introduction
Tripeptidyl peptidase II (TPPII) is the largest known 
protease complex in eukaryotic cells (6MDa) [1]. TPPII 
involvement in several cellular processes has been 
previously described; however, presently its function 
still remains enigmatic [2]. This giant peptidase acts 
primarily downstream of the ubiquitin-proteasome 
system (UPS), by degrading and trimming oligopep-
tides generated by the proteasome [3–6].
In normal conditions, the function of TPPII can be 
replaced by other proteases, as has been demonstrat-
ed in studies in TPPII-deficient mice [7]. However, 
during periods of stress in addition to states affecting 
the function of UPS, TPPII has been shown to sup-
port and substitute the UPS-dependent cytoplasmic 
proteolysis maintaining homeostasis in the cell [8].
Available data indicate that TPPII plays a role in 
the proliferation and survival of malignant lymphoid 
cells. For example, up-regulation of TPPII was re-
ported in EL4 lymphoma cells adapted to grow in the 
presence of proteasome inhibitors [5, 9]. Conversely, 
transfection resulting in the overexpression of TPPII, 
generated increased resistance of lymphoma cells 
against proteasome inhibitors as compared to the 
control non-transfected cells [10]. Accelerated cell 
growth and mitotic infidelity with centrosome dupli-
cation errors were observed in cells overexpressing 
TPPII. Inhibition or siRNA silencing of TPPII in these 
cells resulted in mitotic aberrations and diminished 
cell division rate [11, 12]. In addition, overexpression 
of TPPII protected cells against activity of mitotic 
inhibitors [13].
The overexpression of some oncogenes, for ex-
ample c-myc, resulted in up-regulation of TPPII [14]. 
Furthermore, it was shown that treatment of Burkitt 
lymphoma cells with upregulated TPPII expression 
with AAF-cmk, a membrane permeable semi-specific 
TPPII inhibitor, reduced cell proliferation and in-
duced apoptosis [14]. The similar effect was observed 
in c-myc overexpressing Burkitt lymphoma cells for 
more specific but low membrane permeable TPPII 
inhibitor — butabindide [15].
Cancer cells can adopt proteolytic machinery to 
the stressful conditions inside a tumor including 
increased deubiquitination or decreased proteas-
ome activity that results in resistance to proteasome 
inhibitors and increased activity of TPPII [14, 16]. 
For example, stress related with nutritional starva-
tion, resulted in TPPII upregulation in lymphoma 
cells both in vitro and in vivo [16]. These observa-
tions have given rise to the hypothesis that TPPII 
contributes to antiapoptotic phenotype of some 
cancer cells [11].
Moreover, exposure to DNA-damaging anticancer 
drugs, led to TPPII translocation from the cytoplasm 
to the cell nucleus in the MAP kinase-dependent 
pathway [17]. The inhibition of TPPII by AAF-cmk 
can synergistically potentiate cell death induced by 
pro-apoptotic cytokines, as it was shown for TRAIL 
and TNFa in human leukemic U937 cells [18]. 
AAF-cmk is an irreversible cell membrane perme-
able inhibitor of TPPII. In cellular models (human 
renal carcinoma BB64-RCC and human embryonic 
kidney HEK293 or leukemic EL4) AAF-cmk ef-
fectively inhibits the TPPII activity when added to 
the cell culture at concentration starting from 5 µM 
[5, 19, 20]. However, in concentrations higher than 
50 µM AAF-cmk also inhibits bleomycin hydrolase 
and puromycin-sensitive aminopeptidase [21] and 
may interfere with the chymotrypsin-like activity of 
the proteasome [6]. Therefore, for our study we used 
AAF-cmk at concentrations lower than 50 µM, which 
is declared as TPPII specific.
The aim of the study was to examine the effect 
of AAF-cmk on proliferation, apoptosis, and ultras-
tructure of human leukemic U937 cells to gain insight 
into the intracellular alterations induced by this cell 
membrane-permeable TPTII inhibitor. 
Material and methods
Reagents. Ala-Ala-Phe-chloromethylketone, AAF-cmk 
and z-VAD-fmk (all purchased from Sigma, St. Louis, MO, 
USA) were dissolved in dimethylsulfoxide (DMSO) and 
stored as a 10 mM stock solutions at –20°C. Recombinant 
human TNF (rhTNF produced in E. coli was kindly provid-
ed by Dr. W. Stec (Department of Bioorganic Chemistry, 
Center of Molecular and Macromolecular Studies, Lodz, 
Poland). The specific activity of the rhTNFa was 4.3 ± 1.1 × 
× 107 U/mg protein. 
Cell culture. U937 cells (ATCC) were cultured in standard 
conditions as described in [18]. Shortly, cells were cultured 
in RPMI-1640 medium with stable glutamine (Biochrom, 
Berlin, Germany) supplemented with 10% heat-inactivated 
fetal calf serum (FCS) (Biochrom), 1% Antibiotic–Anti-
mycotic (Thermo Fisher/LifeTechnologies, Waltham, MA, 
USA) in 25 cm2 tissue flasks (Greiner, Berlin, Germany) 
and kept at 37°C in a 5% CO2 humidified atmosphere and 
passaged every 2–3 days.
Cytotoxicity assay. The cytostatic/cytotoxic effects of 
AAF--cmk on U937 cells in vitro was assayed by a standard 
MTT test as previously described [22]. Cells (5 × 103) were 
dispensed into 96-well microtiter plates (Becton Dickinson, 
Franklin, NJ, USA) and incubated with AAF-cmk and/or 
with pan-caspase inhibitor zVAD-fmk 4 h before addition 
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of AAF-cmk for 48 h in a final volume of 200 µL/well. 
Appropriate volumes of culture medium, supplemented 
with DMSO (< 0.1%) were added as controls. Plates were 
read on an FLUOstar Omega Microplate Reader (BMG 
LABTECH, Ortenberg, Germany) using a 550 nm filter. 
Cytostatic/cytotoxic effect was expressed as relative viability 
of control U937 cells [22].
Annexin V binding assay. Phosphatidylserine externali-
zation of apoptotic cells was visualized by staining with 
annexin V-FITC Fluorescence Microscopy Kit according 
to the manufacturer’s instructions (Becton Dickinson). The 
number of Annexin V-FITC positive cells was calculated 
under JuliStage epifluorescent microscope (NanoEnTek, 
Seoul, Korea). 
Western blot analysis and antibodies. Cell lysates were 
assayed by a standard SDS-PAGE, subjected to semi-dry 
transfer onto nitrocellulose membrane and probed with 
appropriate primary and secondary antibody (all from Santa 
Cruz Biotechnology, Santa Cruz, CA, USA). The signal was 
visualized by the chemiluminescence method described by 
Mlynarczuk-Bialy et al. [23].
Transmission electron microscopy. For electron microsco-
py cells were double washed in phosphate-buffered saline 
(PBS) and immediately fixed in 2.5% glutaraldehyde EM 
grade (Merck, Darmstadt, Germany) and 2% paraformal-
dehyde (Sigma, St. Louis, MO, USA) in 0.1 M cacodylate 
buffer (pH 7.4) for 1.5 h, postfixed in 1% OsO4 in 0.1 M 
cacodylate buffer (pH 7.4) for 1 h, dehydrated in graded 
alcohol and embedded in Spurr resin (Sigma). Ultrathin 
sections were placed onto copper grids and contrasted 
with uranyl acetate and lead citrate (Merck). The sections 
were observed at 5500–6000× primary magnification with 
a JEOL JEM 100 S electron microscope (Jeol, Tokyo, 
Japan) at 80 kV.
Statistical analysis. Data was presented as means and 
standard deviation (SD). Differences between groups were 
analyzed for significance by Student’s t-test using Micro-
soft Excel (Microsoft, Redmond, WA, USA). A series of 
independent experiments were performed and the results 
presented in the paper are representative. 
Results
AAF-cmk decreases viability of U937 leukemic cells 
An MTT assay was used to assess the influence of 
AAF-cmk on cell viability. The results are displayed 
as percentage of control cells that were incubated with 
corresponding volume of AAF-cmk solvent. 
AAF-cmk displayed cytotoxic/cytostatic effect on 
leukemic U937 cells in a time- and dose-dependent 
manner. After 24 h of incubation with AAF-cmk, cell 
viability was moderately reduced for both (20 µM and 
40 µM) concentrations. The cell viability was reduced 
to 61.2% ± 5.16 (mean and standard deviation) for 
40 µM AAF-cmk, whereas 20 µM AAF-cmk reduced 
it to 79.4% ± 2.34 (Fig. 1A). After 48 h of incuba-
tion with the inhibitor, cell viability was reduced to 5 
9.2% ± 2.65 and 41.5% ± 2.45 for 20 µM and 
40 µM AAF-cmk, respectively (Fig. 1B). The calculat-
ed IC50% for 48 h of AAF-cmk was 30 µM.
Caspase inhibition restores the viability  
of AAF-cmk-treated cells
To further characterize the nature of AAF-cmk inhib-
itory effect on cell viability, we investigated the effect 
of pan-caspase inhibitor z-VAD-fmk on the viability 
of cells incubated with AAF-cmk.
As shown in Figure 1C, the inhibition of caspases 
partially eliminated negative action of AAF-cmk on 
cell viability. In AAF-cmk-treated cells (20 µM, 48 h), 
viability was reduced to 59.2% ± 5.18 and in the group 
Figure 1. Viability of U937 cells incubated with AAF-cmk. A. U937cells were incubated with AAF-cmk or DMSO solvent 
at given concentrations for 24 h. B. U937 cells were incubated with AAF-cmk or DMSO solvent at given concentrations for 
48 h. C. U937 cells were pre-incubated with pan-caspase inhibitor zVAD-fmk for 4 h, and then with AAF-cmk for next 48 h. 
Cell viability was assessed by MTT assay as described in Methods. Results are expressed in relation to viability of control cells 
incubated with of DMSO solvent. Bars represent means and SD. *significantly different from control, p < 0.05 (Student t-test).
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pre-incubated with z-VAD-fmk and subsequently in-
cubated with both agents for 48 h it reached 84.8% ± 
± 4.43. Thus, the addition of z-VAD-fmk recovered the 
viability by ca. 25% in comparison to AAF-cmk alone. 
AAF-cmk triggered activation of apoptotic caspases
In order to better characterize caspase dependence 
of AAF-cmk inhibitory action on cell viability, we 
investigated the activation of apoptotic caspases in 
AAF-cmk-treated cells by Western blotting. TNF 
was used as a positive control of apoptosis induction.
As shown in Figure 2A, after incubation with 
cells for 24 h, AAF-cmk (20 µM and 40 µM) led to 
the activation of caspase-9 (lines 2 and 3 left), which 
is responsible for initiating the intrinsic apoptotic 
pathway. We did not observe significant signal in 
the control group (line 1 left), with only slight signal 
in TNF-treated cells (line 4 left). Hence, the signal 
for active caspase-9 was significantly weaker after 
prolonged incubation of cells with AAF-cmk (20 µM 
and 40 µM) for 48 h (lines 2 and 3 right).
Following AAF-cmk treatment for 48 h, a strong 
activation of the executor caspase-3 was observed 
in U937 cells incubated with 40 µM AAF-cmk (line 
3 right). Additionally, the caspase substrate PARP 
demonstrated strong cleavage in these cells. Lower 
signal for active caspase-3 was noted in the group 
treated with 20 µM AAF-cmk (line 4 right) and after 
24 h of AAF-cmk treatment for both inhibitor concen-
trations (lines 2 and 3 left). Furthermore, signal for 
cleaved form of PARP was lower in the same groups. 
In the control cells, there was no active caspase-3 
signal present, and the signal for cleaved PARP form 
was low (lines 1 left and right). The positive apoptosis 
inducer TNF caused strong caspase-3 activation and 
PARP cleavage in both incubation periods (lines 
4 left and right). 
AAF-cmk induces externalization  
of phosphatidylserine in U937 cells
An Annexin V-FITC assay was performed to quantify 
effects of AAF-cmk on apoptosis. 
As shown in Figure 2B (dark columns), we ob-
served a dose and time-dependent increase in cells 
positive for Annexin V-FITC. In control groups, we 
observed a minimal ratio of Annexin V-FITC positive 
cells.
The maximal amount of Annexin V binding cells 
was detected after 48 h in cells incubated with 40 µM 
AAF-cmk. In this group 61.2% ± 8.56 of cells were 
positive for Annexin V-FITC whereas in the cells 
treated with 20 µM AAF-cmk for 48 h — 41.5% ± 
± 6.25. Hence, after incubation for 24 h the percentage 
of annexin positive cells was 20.5% ± 6.25 for 20 µM 
and 37.8% ± 4.25 for 40 µM AAF-cmk (Fig. 2B).
AAF-cmk evokes ultrastructural hallmarks  
of apoptosis and autophagy with ALiSNER formation
Following 24 h of incubation, the lower AAF-cmk 
concentration (20 µM) did not demonstrate evident 
ultrastructural features of apoptosis (Fig. 3A). 
Cells incubated with higher AAF-cmk concen-
tration (40 µM) after the same time, early apoptotic 
signs were observed including: (1) irregular conden-
sation of chromatin under the nuclear envelope, (2) 
electron-translucent crescent shaped spaces (CSS) 
in perinuclear area (Fig. 3B) corresponding to ultra-
structural stage I of apoptosis. The higher AAF-cmk 
concentration (40 µM) at the 24h time point featured 
numerous electron-translucent vesicles and autophag-
ic structures of ER-origin (Fig. 3B, G).
Figure 2. Apoptosis induction in U937 by AAF-cmk. 
A. Caspases activation and PARP cleavage by AAF-cmk in 
U937 leukemic cells. U937 cells were incubated for 24 h or 
48 h with: line 1 — DMSO (control), line 2 — AAF-cmk 
20 µM, line 3 — AAF-cmk 40 µM, line 4 — TNF (0.01 ng/ml 
— positive control). Cleaved caspase 9 and 3, PARP was 
analyzed by Western-blotting with appropriate antibodies. 
b-tubulin displayed as a loading control. B. Phosphatidylserine 
externalization induced by AAF-cmk in U937 leukemic cells. 
U937 cells were incubated with AAF-cmk or DMSO solvent 
at given concentrations for 24 h and 48 h. Phosphatidylserine 
externalization was detected by AnnexinV-FITC staining. 
Bars represent means and SD. *significantly different from 
control, p < 0.05 (Student t-test).
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As shown in Figs 3C and 3D, autophagy was in-
itiated by phagophore formation via engulfment of 
cytoplasm by isolation membranes (at the lower in-
hibitor concentration). Phagophores were observed as 
cup-shaped structures of ER origin. Higher inhibitor 
concentration resulted in presence of more advanced 
autophagic structures (Fig. 3E, F). Autophagosome 
formation was observed as a double membrane struc-
Figure 3. Ultrastructure of U937 cell incubated with AAF-cmk for 24 or 48 hours. A–J: U937 cells were treated with AAF-cmk 
for 24 h. A. AAF-cmk 20 µM. B. AAF-cmk 40 µM. C–E. Autophagosome formation (phagophore): C, D — AAF-cmk 20 Mm; 
E — AAF-cmk 40 µM. F. Early double-membrane autophagosome (AAF-cmk 40 µM). G. Vacuolization of endoplasmic 
reticulum (ER) at 40 µM AAF-cmk. H. Aggresome-like structure (ALIS) within the ER-rich cytoplasm at AAF-cmk. I–J. 
ALiSNER within the cytoplasm surrounded by ribosomes at 20 µM AAF-cmk, and 40 µM AAF-cmk (J). K–T: U937 cells 
were treated with AAF-cmk for 48 h. K. The representative cells incubated with AAF-cmk 20 µM. L. The representative 
cells incubated with AAF-cmk 40 µM. M-S. Secondary autophagic structures (AAF-cmk 20 µM). T. Secondary regressive 
changes in cytoplasm (AAF-cmk 40 µM). Scale bars: A, B — 2.50 µm; C, F — 1 µm; G — 100 nm; H — 500 nm; I, J — 200 nm; 
K, L — 5 µm; M-T — 500 nm.
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ture with an electron-translucent space between them 
(Fig. 3F). Apart from electron-translucent vacuoles, 
a number of vesicles containing digested material rep-
resenting lysosomes were observed (Fig. 3G). Among 
these structures of ER-rich cytoplasm, electron-dense 
aggregates of proteins were noted (Fig. 3H). The sec-
ond type of aggregate was found in close proximity to 
free cytosolic ribosomes (Fig. 3I, J).
After 48 h of the incubation of cells with the 
studied inhibitor, late apoptotic and late autophagic 
characteristics were observed. Chromatin under-
went further condensation while the nuclei were 
occasionally fragmented (Fig. 3K, L). The cytoplasm 
underwent secondary regressive changes leading to 
cytoplasm disintegration. 
As visualized in Figure 3K in U937 cells incubated 
for 24 h with lower AAF-cmk concentration (20 µM), 
the chromatin was condensed as either non-protrud-
ing crescents (left cell), or large formed clumps which 
pressed against the nuclear envelope forming buds 
(right cell), corresponding to the ultrastructural stage 
II of apoptosis.
The incubation with higher concentration of AAF-
-cmk (40 µM) resulted in nuclear fragmentation by 
pinching off nuclear fragments (Fig. 3L left cell) or 
nuclear disintegration (Fig. 3L right cell). The ultra-
structural changes in this group represented stage III 
of apoptosis accompanied by secondary regressive 
necrotic changes. 
The late autophagic changes, included presence 
of autophagolysosomes with electron-dense digested 
material (Fig. 3M, N, S). Numerous vesicles of lysoso-
mal origin were also visualized within the cytoplasm 
(Fig. 3T).
Discussion
Extralysosomal proteolysis is involved in the regu-
lation of many key cellular processes through the 
degradation of crucial regulatory proteins that are 
involved in mediating cell proliferation and cell death 
[24]. The main component of this protein breakdown 
pathway is the proteasome which is supplemented by 
action of TPPII.
Two TPPII inhibitors are available commercially: 
AAF-cmk and butabindide. AAF-cmk inhibitor is 
potent irreversible, and membrane permeable [5, 20, 
25]. It slightly but not significantly interferes with the 
chymotrypsin-like activity of the proteasome [6]. How-
ever, in concentrations higher than 50 µM it inhibits 
also bleomycin hydrolase and puromycin-sensitive 
aminopeptidase and other serine and cysteine pro-
teases [21]. For this reason we have used AAF-cmk 
in concentration lower than 50 µM. However, the 
interpretation of any biological effects of AAF-cmk in 
terms of TPPII inhibition must be done with caution.
Butabindide is a TPPII specific reversible and 
competitive inhibitor but has low membrane perme-
ability [26–28]. Moreover it is instable in aqueous 
solutions and even small amounts of fetal calf serum 
in culture media prevent the inhibitory effect of 
butabindide in vitro, thus, its action can be observed 
only in serum-free systems [26, 29]. Therefore, all 
negative results obtained using butabindide as the 
inhibitor [30] must be treated very warily so that AAF-
-cmk has better transitional potential for any clinical 
application. Recently, a novel selective, irreversible 
membrane permeable inhibitor of TPPII, B6, was 
reported but up to now it is not commercially available 
[31]. Furthermore, siRNA-based inhibitory strategies 
are also no perfect for TPPII silencing because they 
allow to obtain a downregulation of TPPII expression 
only up to sixty percent [29]. Taken into consideration 
all information given above AAF-cmk has the best 
translational potential among the available TPPII 
inhibitory strategies and was used by us in this study 
in the concentrations declared as TPPII specific.
Targeting extralysosomal proteolysis by pro-
teasome inhibitors is a well established anticancer 
strategy, especially in hematological malignancies. 
The hematological cell line U937, which is of human 
monocytic leukemia origin, was demonstrated to be 
very sensitive to proteasome inhibition [32]. In this 
study, we showed that the incubation of U937 cells 
with AAF-cmk results in cell death by inducing ap-
optosis and autophagy.
Apoptosis induction is a preferable anti-tumor 
strategy in tumor therapy, and this process of cell 
death is induced by several anticancer agents [33]. 
Biochemically, apoptosis is initiated and executed by 
the action of caspases that lead to nuclease activation 
and thereby internucleosomal DNA cleavage. Apop-
tosis can be designated into two pathways: intrinsic, 
through the recruitment of caspase 9, and extrinsic, 
which is activated by various ligands including TNF. 
Both pathways lead to the activation of caspase 
3 as a common pathway. The plasma membrane of 
the apoptotic cell is intact but undergoes changes in 
phospholipid distribution. Phosphatidylserine is ex-
ternalized from the inner to outer plasma membrane 
leaflet so that phosphatidylserine can be detected via 
annexin V binding.
In our study we have demonstrated that AAF-cmk 
decreased U937 cell viability what can be qualified 
as cytotoxic/cytostatic effect in vitro. Moreover, the 
obtained viability reduction was correlated with the 
number of apoptotic cells detected by annexin V 
binding. AAF-cmk induced apoptosis via the intrinsic 
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pathway by activation of caspase 9 after 24 h of incu-
bation. We did not observe significant caspase 9 acti-
vation upon TNF action, which is known to act along 
the extrinsic pathway. At this time point, AAF-cmk 
caused only slight caspase 3 activation in comparison 
to TNF. After 48 hours the TPPII inhibitor induced 
apoptosis with the activation of the executor caspase 3, 
with no further signaling observed for caspase 9. 
Execution of apoptosis upon AAF-cmk is delayed in 
comparison to TNF, however, caspase 3 activation 
obtained with higher inhibitor concentration is com-
parable to that of TNF.
The discussed above biochemical changes in U937 
cells were followed by parallel ultrastructural changes. 
At the ultrastructural level, apoptosis is characterized 
by several morphological changes within the nucleus. 
The chromatin becomes pyknotic and condensed into 
half-moon shape clumps enclosed within the nuclear 
envelope. The nucleus undergoes karyorrhexis (frag-
mentation) by two possible mechanisms, i.e. budding 
and cleavage [34, 35]. The process of nuclear changes 
during apoptosis, can be divided into four stages [36]. 
The first ultrastructural hallmark of apoptosis is oc-
currence of crescent-shaped spaces (CSS) around the 
nuclear envelope [36]. 
In U937 treated with AAF-cmk, the first ultras-
tructural stage of apoptosis is detectable after 24 hours 
of inhibitor administration. This observation coincides 
with initiatory caspase activation observed at the same 
time point. Hence, after 48 hours of inhibitor action, 
most of cells correspond to ultrastructural stage II (at 
lower AAF-cmk concentration) or stage III (higher 
concentration of inhibitor) of apoptosis. In the group 
with maximal caspase 3 activation (AAF-cmk 40 µM, 
48 h), ultrastructural changes are most pronounced. 
These cells present ultrastructural stage III/IV of 
apoptosis with karyorrhexis as a sign of apoptotic 
body formation (stage IV). The observed dominating 
nucleus fragmentation takes place by the budding 
mechanism.
Moreover, TEM examination revealed that U937 
cells responded to AAF-cmk with autophagy induc-
tion and aggregation of proteins. The formation of 
protein aggregates under proteasome inhibition was 
first reported by Wojcik et al. in 1996 [37–39] and was 
termed as aggresomes’ formation [40]. Aggresomes 
are localized in the perinuclear ER-rich region, in 
the proteolytic center of the cell, and form one large 
structure containing proteasomes and undigested 
proteins. However, such multifocal type of proteins’ 
aggregates may also be observed in cells upon IFN-g 
stimulation that leads to increased protein synthesis. 
This increased amount of newly synthesized proteins 
exceeds degradation capability of standard protea-
somes resulting in protein aggregation [41]. These 
multifocal structures are termed aggresome-like 
structures — ALIS and were first described as DALIS 
in dendritic cells during their maturation [42, 43]. All 
these structures accumulate mainly newly synthesized 
proteins from Defective ribosomal Products (DRiPs) 
fraction with T1/2 of ca. 10 minutes [42, 43]. The DRiP 
can constitute up to 30% of newly synthesized proteins 
and are degraded by UPS [44]. 
Both aggresomes and ALIS have been shown to 
be substrates for autophagy [37, 43, 45, 46]. However, 
autophagy is not the general mechanism for clearance 
of such protein aggregates [47]. Previous investiga-
tions demonstrated that TPPII inhibition decreases 
activity of pERK1/2, which belong to the MAP kinases 
family [31]. Activation of the MAP kinase signaling 
pathway is one of the most potent prosurvival signals 
in cancer cells. MAP activates downstream mTOR 
and its inhibition was shown to be one of the key 
regulators of autophagy [48]. Moreover, cross-talk 
between autophagy and apoptosis with several pro-
teins has been demonstrated in these two processes 
[49, 50]. Additionally, autophagy induction can result 
in cell death and this process is referred as autophagic 
cell death [51, 52]. In our study, the ultrastructural 
features of both autophagic and apoptotic cell death, 
accompanied by secondary necrotic changes, were 
observed in the same cells.
As TPPII acts primarily downstream to the protea-
some, its inhibition can slow proteasome-dependent 
proteolysis by a feedback loop mechanism, resulting 
in protein aggregation. In addition, AAF-cmk is 
known to slightly inhibit chymotrypsin-like activity of 
the proteasome without affecting its other activities 
[6]. However, inhibition of only one activity is not 
sufficient to completely prevent degradation of DRiPs 
[53]. Moreover, in U937 cells AAF-cmk was shown 
to induce G0/G1 cell cycle arrest hence proteasome 
inhibitor (PSI) G2 arrest [6]. Thus the effect of AAF-
-cmk on U937 probably does not depend on marginal 
inhibition of chymotripsin-like proteasome activity 
by this agent.
In our in vitro model we observed two types of 
protein aggregates. The first type was surrounded 
by ER elements, corresponding to aggresomes or 
ALIS in the perinuclear region. Furthermore, these 
aggregates were surrounded by many lysosomal 
structures, thereby suggesting their involvement in 
autophagy induction. The second type of aggregates 
was not related to ER elements, but rather to free 
cytosolic ribosomes. This type did not correspond to 
the aggresome neither in localization, nor in the struc-
ture, and we refer to these aggregates as ALiSNER 
(Aggresome-Like Structure Not Associated With the 
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ER). Their presence can be interpreted as a possible 
sign of impaired co-translational degradation of pro-
teins on free ribosomes. During protein synthesis, the 
free N-terminus protrudes from the free ribosome, 
and as TPPII is an N-terminal peptidase, we suggest 
that TPPII can be potentially directly involved in 
trimming of such nascent proteins. In contrast to the 
proteasome, little is known about the involvement of 
TPPII in the degradation of nascent proteins, how-
ever, TPPII has been recently shown to be localized 
in close proximity to proteasome [54]. Moreover, we 
have recently shown in colon adenocarcinoma C26 
cells that TPPII is recruited into aggresomes upon 
proteasome inhibition [55].
As discussed above, TPPII has been linked with 
proliferation and survival of lymphoma cells and 
some nonlymphoid tumor cells. These studies were 
conducted with either TPPII inhibitors, TPPII-specific 
siRNA, or overexpression of TPPII. However, AAF-
cmk itself has been never systematically examined 
in the context of tumor cell growth and apoptosis 
induction mechanism. Except our research there are 
published only few data on the AAF-cmk effect on 
tumor cell viability. All published data are displayed 
as controls for the biochemical experiments with both 
TPPII or/and proteasome inhibitors. In this context 
AAF-cmk was examined in leukemia cells EL4 and 
Burkitt lymphoma cells. In EL4 leukemia cells (mouse 
lymphoblast lymphoma) adapted to the proteasome 
inhibitor, AAF-cmk in the concentration of 20 µM 
reduced the cell viability by 80% after 24h incubation 
[56]. In Burkitt lymphoma cells 10 µM AAF-cmk 
inhibited growth by 50% after 48h of incubation. 
Hence 100 µM AAF-cmk completely inhibited the cell 
growth [30]. However, AAF-cmk at this concentration 
(100 µM) is not TPPII specific [6]. 
Thus, the concentration of AAF-cmk applied by 
other researchers on tumor cells is comparable with 
the concentrations used by us. Also the average effect 
of AAF-cmk on cell growth is similar to our results. 
Moreover we provide novel ultrastructural data on pro-
tein aggregation in U937 cells induced by AAF-cmk.
In summary, AAF-cmk reduces viability of leu-
kemic U937 cells and its action results in the forma-
tion of two types of cytoplasmic aggregates, triggering 
of intrinsic apoptosis and autophagy. Further trans-
lational study would evaluate application potential 
of this TPPII inhibitor and detailed mechanism of its 
cytotoxic activity.
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